tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncowebtumors-284Research ArticleСтатьиМОЛЕКУЛЯРНО-ГЕНЕТИЧЕСКИЕ ОСОБЕННОСТИ КЛИНИЧЕСКОГО ПРОГНОЗА ГЦРЛазаревичН. Л.LazarevichN. L.

Лазаревич Наталия Леонидовна — НИИ Канцерогенеза РОНЦ им. Н. Н. Блохина, биологический факультет МГУ им. М. В. Ломоносова,  Москва

lazarevich.nl@gmail.comКривцоваО. М.KrivtsovaО. M.

Кривцова Ольга Михайловна — НИИ Канцерогенеза РОНЦ им. Н. Н. Блохина, биологический факультет МГУ им. М. В. Ломоносова, Москва

СковородниковаП. А.SkovorodnikovaP. A.

Сковородникова Полина Андреевна — НИИ Канцерогенеза РОНЦ им. Н. Н. Блохина, биологический факультет МГУ им. М. В. Ломоносова, Москва

Научно-исследовательский институт канцерогенеза Российского онкологического научного центра имени Н.Н. Блохина; Московский государственный университет имени М.В.ЛомоносоваRussian Federation20161811201604s14045Copyright © Лазаревич Н.Л., Кривцова О.М., Сковородникова П.А., 20162016Лазаревич Н.Л., Кривцова О.М., Сковородникова П.А.Lazarevich N.L., Krivtsova О.M., Skovorodnikova P.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/284

Гепатоцеллюлярный рак (ГЦР) — одна из наиболее распространенных форм злокачественных новообразований, характеризующаяся поздними сроками выявления, устойчивостью к химиотерапии и крайне неблагоприятным прогнозом. Молекулярно-биологические исследования последних лет показали, что по спектру вызывающих его молекулярных событий этот тип опухолей является крайне гетерогенным.

В настоящем  обзоре рассмотрены основные молекулярно-генетические нарушения, характерные для ГЦР, роль хронической инфекции  вирусами гепатита В и С в развитии опухолей, проблема опухолевой гетерогенности и другие сложности и ограничения, препятствующие разработке действенных подходов к прогнозированию течения болезни и выбору оптимальной тактики лечения. Рассмотренные данные указывают на то, что разделение случаев ГЦР на отдельные субклассы в зависимости от их этиологических, морфологических  или генетических особенностей может позволить идентифицировать достоверные факторы прогноза внутри отдельных групп и оптимизировать подходы к выбору мишеней для направленной терапии.

гепатоцеллюлярный ракмутациитранскриптомопухолевая гетерогенностьфакторы прогнозаReferencesTorre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2): 87–108.Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2): 87–108.Marquardt JU, Galle PR, Teufel A. Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): An emerging field for advanced technologies. J Hepatol. 2012; 56(1): 267–275.Marquardt JU, Galle PR, Teufel A. Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): An emerging field for advanced technologies. J Hepatol. 2012; 56(1): 267–275.Calvisi DF, Frau M, Tomasi ML, Feo F, Pascale RM. Deregulation of signalling pathways in prognostic subtypes of hepatocellular carcinoma: Novel insights from interspecies comparison. Biochim Biophys Acta — Rev Cancer. 2012; 1826(1): 215–237.Calvisi DF, Frau M, Tomasi ML, Feo F, Pascale RM. Deregulation of signalling pathways in prognostic subtypes of hepatocellular carcinoma: Novel insights from interspecies comparison. Biochim Biophys Acta — Rev Cancer. 2012; 1826(1): 215–237.Schulze K, Nault JC, Villanueva A. Genetic profiling of hepatocellular carcinoma using next-generation sequencing. J Hepatol. 2016. pii: S0168–8278(16)30249–5.Schulze K, Nault JC, Villanueva A. Genetic profiling of hepatocellular carcinoma using next-generation sequencing. J Hepatol. 2016. pii: S0168–8278(16)30249–5.Han ZG. Functional Genomic Studies: Insights into the Pathogenesis of Liver Cancer. Annu Rev Genomics Hum Genet. 2012; 13(1): 171–205.Han ZG. Functional Genomic Studies: Insights into the Pathogenesis of Liver Cancer. Annu Rev Genomics Hum Genet. 2012; 13(1): 171–205.Lee JS, Chu IS, Heo J., Calvisi DF, Sun Z, Roskams T, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology. 2004; 40: 667–676.Lee JS, Chu IS, Heo J., Calvisi DF, Sun Z, Roskams T, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology. 2004; 40: 667–676.Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP, Chiang DY, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res. 2009; 69: 7385–7392.Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP, Chiang DY, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res. 2009; 69: 7385–7392.Boyault S, Rickman DS, De Reyni s A, Balabaud C, Rebouissou S, Jeannot E, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology. 2007; 45: 42–52.Boyault S, Rickman DS, De Reyni s A, Balabaud C, Rebouissou S, Jeannot E, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology. 2007; 45: 42–52.Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D, Alsinet C, et al. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology. 2011; 140(5): 1501–12.e2.Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D, Alsinet C, et al. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology. 2011; 140(5): 1501–12.e2.Nault JC, De Reynies A, Villanueva A, Calderaro J, Rebouissou S, Couchy G, et al. A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology. 2013; 145: 176–187.Nault JC, De Reynies A, Villanueva A, Calderaro J, Rebouissou S, Couchy G, et al. A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology. 2013; 145: 176–187.Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med. 2008; 359: 1995–2004.Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med. 2008; 359: 1995–2004.Ji J, Yu L, Yu Z, Forgues M, Uenishi T, Kubo S, et al. Development of a miR-26 companion diagnostic test for adjuvant interferon-alpha therapy in hepatocellular carcinoma. Int J Biol Sci. 2013; 9(3): 303–12.Ji J, Yu L, Yu Z, Forgues M, Uenishi T, Kubo S, et al. Development of a miR-26 companion diagnostic test for adjuvant interferon-alpha therapy in hepatocellular carcinoma. Int J Biol Sci. 2013; 9(3): 303–12.Tsai WL, Chung RT. Viral hepatocarcinogenesis. Oncogene. 2010; 29(16): 2309–2324.Tsai WL, Chung RT. Viral hepatocarcinogenesis. Oncogene. 2010; 29(16): 2309–2324.Röcken C, Carl-McGrath S. Pathology and Pathogenesis of Hepatocellular Carcinoma. Dig Dis. 2001; 19(4): 269–278.Röcken C, Carl-McGrath S. Pathology and Pathogenesis of Hepatocellular Carcinoma. Dig Dis. 2001; 19(4): 269–278.Mesri EA, Feitelson MA, Munger K. Human viral oncogenesis: A cancer hallmarks analysis. Cell Host Microbe. 2014; 15(3): 266–282.Mesri EA, Feitelson MA, Munger K. Human viral oncogenesis: A cancer hallmarks analysis. Cell Host Microbe. 2014; 15(3): 266–282.Marquardt JU, Seo D, Andersen JB, Gillen MC, Kim MS, Conner EA, et al. Sequential transcriptome analysis of human liver cancer indicates late stage acquisition of malignant traits. J Hepatol. 2014; 60(2): 346–53.Marquardt JU, Seo D, Andersen JB, Gillen MC, Kim MS, Conner EA, et al. Sequential transcriptome analysis of human liver cancer indicates late stage acquisition of malignant traits. J Hepatol. 2014; 60(2): 346–53.Nakashima O, Kojiro M. Recurrence of hepatocellular carcinoma: multicentric occurrence or intrahepatic metastasis? A viewpoint in terms of pathology. J Hepatobiliary Pancreat Surg. 2001; 8(5): 404–409.Nakashima O, Kojiro M. Recurrence of hepatocellular carcinoma: multicentric occurrence or intrahepatic metastasis? A viewpoint in terms of pathology. J Hepatobiliary Pancreat Surg. 2001; 8(5): 404–409.Miao R, Luo H, Zhou H, Li G, Bu D, Yang X, et al. Identification of prognostic biomarkers in hepatitis B virus-related hepatocellular carcinoma and stratification by integrative multi-omics analysis. J Hepatol. 2014; 61(4): 840–849.Miao R, Luo H, Zhou H, Li G, Bu D, Yang X, et al. Identification of prognostic biomarkers in hepatitis B virus-related hepatocellular carcinoma and stratification by integrative multi-omics analysis. J Hepatol. 2014; 61(4): 840–849.Консервативное лечение первичного и метастатического рака печени / Под ред. В. А. Горбуновой. — 288 c., М.: ООО «Медицинское информационное агентство», 2013.Консервативное лечение первичного и метастатического рака печени / Под ред. В. А. Горбуновой. — 288 c., М.: ООО «Медицинское информационное агентство», 2013.Xue R, Li R, Guo H, Guo L, Su Z, Ni X, et al. Variable Extent of Intra-tumor Heterogeneity Revealed by Genomic Sequencing of Multiple Lesions in Patients with Hepatocellular Carcinoma. Gastroenterology. 2016; 150(4): 998–1008.Xue R, Li R, Guo H, Guo L, Su Z, Ni X, et al. Variable Extent of Intra-tumor Heterogeneity Revealed by Genomic Sequencing of Multiple Lesions in Patients with Hepatocellular Carcinoma. Gastroenterology. 2016; 150(4): 998–1008.Wang B, Xia CY, Lau WY, Lu XY, Dong H, Yu WL, et al. Determination of clonal origin of recurrent hepatocellular carcinoma for personalized therapy and outcomes evaluation: a new strategy for hepatic surgery. J Am Coll Surg. 2013; 217(6): 1054–1062.Wang B, Xia CY, Lau WY, Lu XY, Dong H, Yu WL, et al. Determination of clonal origin of recurrent hepatocellular carcinoma for personalized therapy and outcomes evaluation: a new strategy for hepatic surgery. J Am Coll Surg. 2013; 217(6): 1054–1062.Matsumoto Y, Fujii H, Matsuda M, Kono H. Multicentric occurrence of hepatocellular carcinoma: diagnosis and clinical significance. J Hepatobiliary Pancreat Surg. 2001; 8(5): 435–440.Matsumoto Y, Fujii H, Matsuda M, Kono H. Multicentric occurrence of hepatocellular carcinoma: diagnosis and clinical significance. J Hepatobiliary Pancreat Surg. 2001; 8(5): 435–440.Li Q, Wang J, Juzi JT, Sun Y, Zheng H, Cui Y, et al. Clonality analysis for multicentric origin and intrahepatic metastasis in recurrent and primary hepatocellular carcinoma. J Gastrointest Surg. 2008; 12(9): 1540–1547.Li Q, Wang J, Juzi JT, Sun Y, Zheng H, Cui Y, et al. Clonality analysis for multicentric origin and intrahepatic metastasis in recurrent and primary hepatocellular carcinoma. J Gastrointest Surg. 2008; 12(9): 1540–1547.Lu LC, Hsu CH, Hsu C, Cheng AL. Tumor Heterogeneity in Hepatocellular Carcinoma: Facing the Challenges. Liver Cancer. 2016; 5(2): 128–138.Lu LC, Hsu CH, Hsu C, Cheng AL. Tumor Heterogeneity in Hepatocellular Carcinoma: Facing the Challenges. Liver Cancer. 2016; 5(2): 128–138.Arii S, Teramoto K, Kawamura T, Okamoto H, Kaido T, Mori A, Imamura M. Characteristics of recurrent hepatocellular carcinoma in Japan and our surgical experience. J Hepatobiliary Pancreat Surg. 2001; 8(5): 397–403.Arii S, Teramoto K, Kawamura T, Okamoto H, Kaido T, Mori A, Imamura M. Characteristics of recurrent hepatocellular carcinoma in Japan and our surgical experience. J Hepatobiliary Pancreat Surg. 2001; 8(5): 397–403.Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Waldman F, Pinkel D. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science. 1992; 258(5083): 818–821.Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Waldman F, Pinkel D. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science. 1992; 258(5083): 818–821.Vogelstein B, Fearon ER, Feinberg AP. Use of restriction fragment length polymorphisms to determine the clonal origin of human tumors. Science. 1985; 227(4687): 642–645.Vogelstein B, Fearon ER, Feinberg AP. Use of restriction fragment length polymorphisms to determine the clonal origin of human tumors. Science. 1985; 227(4687): 642–645.Welsh J, McClelland M. Fingerprinting genomes using PCR with arbitrary primers. Nucleic acids research. 1990; 18(24): 7213–7218.Welsh J, McClelland M. Fingerprinting genomes using PCR with arbitrary primers. Nucleic acids research. 1990; 18(24): 7213–7218.Shi JY, Xing Q, Duan M, Wang ZC, Yang LX, Zhao YJ, et al. Inferring the progression of multifocal liver cancer from spatial and temporal genomic heterogeneity. Oncotarget. 2016; 7(3): 2867.Shi JY, Xing Q, Duan M, Wang ZC, Yang LX, Zhao YJ, et al. Inferring the progression of multifocal liver cancer from spatial and temporal genomic heterogeneity. Oncotarget. 2016; 7(3): 2867.Liu S, Chan KW, Wang B, Qiao L. Fibrolamellar hepatocellular carcinoma. Am. J. Gastroenterol. 2009; 104: 2617–2624.Liu S, Chan KW, Wang B, Qiao L. Fibrolamellar hepatocellular carcinoma. Am. J. Gastroenterol. 2009; 104: 2617–2624.Honeyman JN, Simon EP, Robine N, Chiaroni-Clarke R, Darcy DG, Lim II, et al. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science. 2014; 343(6174): 1010–1014.Honeyman JN, Simon EP, Robine N, Chiaroni-Clarke R, Darcy DG, Lim II, et al. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science. 2014; 343(6174): 1010–1014.Xu L, Hazard FK, Zmoos AF, Jahchan N, Chaib H, Garfin PM, et al. Genomic analysis of fibrolamellar hepatocellular carcinoma. Hum Mol Genet. 2015; 24(1): 50–63.Xu L, Hazard FK, Zmoos AF, Jahchan N, Chaib H, Garfin PM, et al. Genomic analysis of fibrolamellar hepatocellular carcinoma. Hum Mol Genet. 2015; 24(1): 50–63.Cornella H, Alisnet C, Sayols S, Zhang Z, Hao K, Cabellos L, et al. Unique genomic profile of fibrolamellar hepatocellular carcinoma. Gastroenterology. 2015; S0016–5085(14)01580–7.Cornella H, Alisnet C, Sayols S, Zhang Z, Hao K, Cabellos L, et al. Unique genomic profile of fibrolamellar hepatocellular carcinoma. Gastroenterology. 2015; S0016–5085(14)01580–7.Chan SL, Wong AM, Lee K, Wong N, Chan AK. Personalized therapy for hepatocellular carcinoma: Where are we now? Cancer Treat Rev. 2016; 45: 77–86.Chan SL, Wong AM, Lee K, Wong N, Chan AK. Personalized therapy for hepatocellular carcinoma: Where are we now? Cancer Treat Rev. 2016; 45: 77–86.Heindryckx F, Gerwins P. Targeting the tumor stroma in hepatocellular carcinoma. World J Hepatol. 2015; 7(2): 165–176.Heindryckx F, Gerwins P. Targeting the tumor stroma in hepatocellular carcinoma. World J Hepatol. 2015; 7(2): 165–176.Lavi O, Skinner J, Gottesman MM. Network features suggest new hepatocellular carcinoma treatment strategies. BMC Syst Biol. 2014; 8: 88.Lavi O, Skinner J, Gottesman MM. Network features suggest new hepatocellular carcinoma treatment strategies. BMC Syst Biol. 2014; 8: 88.

The authors declare that there are no conflicts of interest present.